BACKGROUND/AIMS: Dysbiosis is associated with various systemic disorders including irritable bowel syndrome (IBS). Fecal microbiota transplantation (FMT) might restore intestinal microbial balance. The study aimed to determine the safety and efficacy of FMT in IBS patients, as well as also positive predictors for FMT. METHODS: This was a single-arm, open-label study. Eligible patients were diagnosed based on Rome III Diagnostic Criteria. Fecal materials were administered to the patient via colonoscopy. The primary end point was a change in the Bristol stool form scale at 4 weeks after FMT. Recovery to types 3-4 was considered a clinical response. The secondary end point was a change in intestinal microbiota and psychological status using the Hamilton Rating Scale. RESULTS: Ten patients were enrolled. Six patients achieved a clinical response. The diversity of patients 4 weeks after FMT increased significantly compared with patients before FMT, and that of responding patients was significantly higher than non-responder patients. The abundance of Bifidobacterium in effective donors was significantly higher than in ineffective donors and patients. Psychological status of all patients was significantly improved after FMT. CONCLUSIONS: FMT for patients with IBS is safe, and relatively effective. Bifidobacterium-rich fecal donor may be a positive predictor for successful FMT. Key Summary: (1) Dysbiosis is associated with various gastrointestinal disorders including IBS. (2) FMT has potential to restore intestinal microbial balance. (3) We showed that FMT improved stool form and psychological status of IBS patients. (4) Bifidobacterium-rich donor efficiently induced symbiosis in IBS patients.
BACKGROUND/AIMS: Dysbiosis is associated with various systemic disorders including irritable bowel syndrome (IBS). Fecal microbiota transplantation (FMT) might restore intestinal microbial balance. The study aimed to determine the safety and efficacy of FMT in IBSpatients, as well as also positive predictors for FMT. METHODS: This was a single-arm, open-label study. Eligible patients were diagnosed based on Rome III Diagnostic Criteria. Fecal materials were administered to the patient via colonoscopy. The primary end point was a change in the Bristol stool form scale at 4 weeks after FMT. Recovery to types 3-4 was considered a clinical response. The secondary end point was a change in intestinal microbiota and psychological status using the Hamilton Rating Scale. RESULTS: Ten patients were enrolled. Six patients achieved a clinical response. The diversity of patients 4 weeks after FMT increased significantly compared with patients before FMT, and that of responding patients was significantly higher than non-responder patients. The abundance of Bifidobacterium in effective donors was significantly higher than in ineffective donors and patients. Psychological status of all patients was significantly improved after FMT. CONCLUSIONS: FMT for patients with IBS is safe, and relatively effective. Bifidobacterium-rich fecal donor may be a positive predictor for successful FMT. Key Summary: (1) Dysbiosis is associated with various gastrointestinal disorders including IBS. (2) FMT has potential to restore intestinal microbial balance. (3) We showed that FMT improved stool form and psychological status of IBSpatients. (4) Bifidobacterium-rich donor efficiently induced symbiosis in IBSpatients.
Authors: F Azpiroz; C Dubray; A Bernalier-Donadille; J-M Cardot; A Accarino; J Serra; A Wagner; F Respondek; M Dapoigny Journal: Neurogastroenterol Motil Date: 2016-07-31 Impact factor: 3.598
Authors: Emma P Halmos; Victoria A Power; Susan J Shepherd; Peter R Gibson; Jane G Muir Journal: Gastroenterology Date: 2013-09-25 Impact factor: 22.682
Authors: Simone S Li; Ana Zhu; Vladimir Benes; Paul I Costea; Rajna Hercog; Falk Hildebrand; Jaime Huerta-Cepas; Max Nieuwdorp; Jarkko Salojärvi; Anita Y Voigt; Georg Zeller; Shinichi Sunagawa; Willem M de Vos; Peer Bork Journal: Science Date: 2016-04-29 Impact factor: 47.728
Authors: Caroline J Tuck; Jane G Muir; Jacqueline S Barrett; Peter R Gibson Journal: Expert Rev Gastroenterol Hepatol Date: 2014-05-15 Impact factor: 3.869
Authors: Magnus Simrén; Giovanni Barbara; Harry J Flint; Brennan M R Spiegel; Robin C Spiller; Stephen Vanner; Elena F Verdu; Peter J Whorwell; Erwin G Zoetendal Journal: Gut Date: 2012-06-22 Impact factor: 23.059
Authors: Kanchana Myneedu; Abhizith Deoker; Max J Schmulson; Mohammad Bashashati Journal: United European Gastroenterol J Date: 2019-07-30 Impact factor: 4.623
Authors: Haseeb Anwar; Arslan Iftikhar; Humaira Muzaffar; Ahmad Almatroudi; Khaled S Allemailem; Soha Navaid; Sana Saleem; Mohsin Khurshid Journal: Biomed Res Int Date: 2021-05-12 Impact factor: 3.411